

### **KNOW LABS**

TRANSFORMING NON-INVASIVE MEDICAL DIAGNOSTICS

Q3 FY2023 Earnings Call NYSE American: KNW


## 2023 YTD Selected Milestones

- Re-organization and re-alignment of resources to core goals
- Generation 1 device reveal
- Accelerated clinical testing
  - >1.5 billion datapoints
  - >300 3-hour datasets collected
  - Multiple protocols
- Scientific validation
  - 5 manuscripts
  - 2 posters (APS and AACE)
- MARD Improvement
  - February 2023: 19.3%
  - May 2023: 12.9%
  - July 2023: 11.3%
- 169 patents issued and pending (#1 in non-invasive blood glucose monitoring)
- Scientific and Technical Advisory Board: 10 members
- Reduced burn rate: \$1.2M/month to \$800k/month



# Sensor Accuracy Progress

### Continuous Glucose Monitoring Accuracy Over Time



### 2023 Lesson Learned

Additional research needed before launching a medical device and presenting our technology and devices to the FDA

### Data accuracy across all glycemic ranges

- >80% of the current data is still in the normal glucose range, 80 to 150 mg/dL
- Include participants with T1D, T2D, pre-diabetes, and other sub-segments
- Patient physiological characteristics
  - Diversify participants' base: skin pigmentations, skin thickness, etc.
  - Test against the presence of other elements and substances that could cause interference: hair, sweat, intense movement, medication, vitamins, etc.
- Environment and human factors
  - Controlled lab environment to real-world application
  - Environment: air pressure, temperature, and humidity
  - Human control of the technology

# Workstreams Implications

- **Data collection**: more participants with diverse backgrounds, including people with Type 1 Diabetes, Type 2 Diabetes, and prediabetes (intended device population).
- Data science and algorithm refinement: more data equals better accuracy.
- **Sensor characterization**: from a controlled environment to real-world applications (outside of the lab).
- Scientific validation: external research institutes to further validate technology and support FDA application.


Increase the generalizability of the Bio-RFID technology platform and algorithm

## Mission

Know Labs is committed to making a difference in the lives of millions of people around the world by developing convenient, accessible and affordable non-invasive medical diagnostics solutions, starting with blood glucose monitoring.

### The Bio-RFID Sensor

### Patented high resolution Bio-RFID sensor can measure anything.



- <u>IP-protected Antenna Array</u> that emits and captures radio wave signals, the "Energy Field"
- <u>IP-protected RF Generator</u> that enables frequency sweeps in the microwave spectrum, from 1,500 MHz to 4,000 MHz, at 0.1 intervals
- ~1.5M data points collected per hour
- Currently focused on blood glucose, but potential to expand into <u>other</u> <u>biomarkers</u>, such as oxygen, ketones, lactate, alcohol, and metabolized drugs


## The Bio-RFID Platform

### **Know Labs' patented non-invasive technology platform.**

RF Spectroscopy	Uses electromagnetic energy to accurately identify and measure a wide range of organic and inorganic materials, molecules, and compositions of matter
Form Factor Agnostic	Integrated into a variety of wearable, mobile or bench-top form factors
Pain-free	No needles nor invasive transmitters poking the skin
No Consumables	Low bill of materials translates into high potential to be 3x-5x less expensive than current FDA-cleared options
ML/AI-Powered Algorithms	Cutting-edge ML/AI powering accurate real-time measurements with high correlation to gold standard
Predictive Health	100+ potential applications beyond blood glucose monitoring, multiple concurrent biomarkers to enable predictive health & monitoring of metabolism

# Overcoming the Limitations of Physics

Bio-RFID safely collects data from the full cellular stack, enabling a comprehensive picture of glucose and other analytes optical sensors are unable to achieve.



### Know Labs Product Portfolio

### **Efficient, Affordable and Completely Non-Invasive Medical Solutions**

Intended Addressable Market: people with diabetes and pre-diabetes, and people with no diabetes interested in monitoring glucose levels



#### KnowU

- On-demand and On-the-Go
- Spot glucose monitoring
- Place your palm over the sensor for a reading of glucose concentration in mg/dL



#### **UBand**

- Continuous
- Wearable
- Ease of use
- Check glucose levels in real-time through the Know Labs app



Know Labs Devices will connect to its smartphone App via Bluetooth and will be available on both the App Store and Google Play

## Data Science Overview

### N = 1Sessions = 11 Datasets = 22KL Data Points ~ 183 mill Reference Data Points 383 Time for data collection ~ 33 hr Population: Healthy no Diabetes


#### N = 5Sessions = 53Datasets = 106KL Data Points ~ 502 mill Reference Data Points 1.664 Time for data collection ~ 150 hr Population: Healthy no Diabetes

Executed

#### N = 13Sessions = 183Datasets = 366 KL Data Points ~ 1.7 bil Reference Data Points 5.425 Time for data collection ~ 550 hr. Population: Healthy no Diabetes



N = 30Sessions = 90Datasets = 180 KL Data Points TBD Reference Data Points TBD Time for data collection TBD Population: Healthy, Pre, T2D



## FY2023 Goals

- Further accelerate data collection
- Continue data science and algorithm refinement
- Finalize Generation 2 design
- Refine regulatory strategy
- Socialize technology with the FDA
- Maintain IP leadership in non-invasive blood glucose monitoring
- Continue growing the organization
- Support business needs with additional capital raise

# Closing Remarks

### Focus on our four core workstreams:

- Data collection
- Data science and algorithm refinement
- Sensor and hardware characterization
- Scientific validation

Reveal Generation 2 device.

Continue strategic development of our intellectual property portfolio.

Increase market activity, with more manuscripts being published.

## THANK YOU

www.knowlabs.co ask@knowlabs.co

# **Know Labs, Inc. NYSE American: KNW**